The Scientific World Journal / 2013 / Article / Tab 2

Research Article

Association of Blood Pressure and Hypertension with Alcohol Consumption in HIV-Infected White and Nonwhite Patients

Table 2

Risk factors for hypertension among HIV-infected individuals by skin color ( (%)).

Whites ( )Nonwhites ( )
Hypertension (%)RR (95% CI)Hypertension (%)RR (95% CI)

Sex
 Female48 (15.0)1.065 (22.2)1.0
 Male72 (18.4)1.2 (0.9–1.7)56 (23.6)1.1 (0.8–1.5)
value0.20.7
Age (years)
 18–3420 (7.4)1.023 (11.4)1.0
 35–4956 (16.9)2.3 (1.4–3.7)63 (24.3)2.1 (1.4–3.3)
 50–7844 (40.4)5.4 (3.4–8.8)35 (50.7)4.5 (2.8–7.0)
value<0.001<0.001
Educational attainment (years)
 ≥958 (17.8)1.023 (17.8)1.0
 5–838 (16.2)0.9 (0.6–1.3)51 (22.2)1.2 (0.8–1.9)
 0–424 (16.0)0.9 (0.6–1.4)47 (27.5)1.5 (1.0–2.4)
value0.80.14
Smoking
 No85 (20.6)1.076 (25.1)1.0
 Yes35 (11.7)0.6 (0.4–0.8)45 (19.8)0.8 (0.6–1.1)
value0.0020.16
Physical activity
 High39 (14.0)1.048 (19.8)1.0
 Moderate44 (19.0)1.4 (0.9–2.0)38 (22.9)1.2 (0.8–1.7)
 Low37 (18.6)1.3 (0.9–2.0)35 (28.7)1.4 (1.0–2.1)
value0.30.16
Alcohol consumption
 Abstemious41 (17.6)1.041 (22.7)1.0
 Social drinking70 (15.9)0.9 (0.6–1.3)68 (21.5)0.9 (0.7–1.3)
 Abusive drinking9 (24.3)1.4 (0.7–2.6)12 (37.5)1.7 (1.0–2.8)
value0.40.08
Frequency of alcohol consumption
 Abstemious41 (18.0)1.041 (22.7)1.0
 Monthly41 (17.6)0.9 (0.6–1.3)42 (26.6)0.9 (0.6–1.3)
 Weekly38 (15.3)1.1 (0.7–1.5)79 (21.2)1.2 (0.8–1.7)
value0.70.3
Binge drinking
 Abstemious41 (17.6)1.041 (22.7)1.0
 No60 (16.7)0.9 (0.7–1.4)60 (23.4)1.0
 Yes19 (16.2)0.9 (0.6–1.5)20 (21.5)1.0 (0.6–1.5)
value0.90.8
Body mass index (kg/m²)
 <25.036 (8.7)1.045 (15.3)1.0
 25–29.958 (26.6)3.1 (2.1–4.5)40 (24.7)1.6 (1.1–2.4)
 ≥30.026 (32.9)3.8 (2.4–5.9)36 (49.3)3.2 (2.3–4.6)
value<0.001<0.001
HIV/HCV coinfection
 No96 (18.0)1.085 (22.1)1.0
 Yes22 (15.4)0.9 (0.6–1.3)29 (24.6)1.1 (0.8–1.6)
value0.50.6
AIDS diagnosis
 No 29 (14.6)1.036 (24.7)1.0
 Yes90 (17.6)0.8 (0.6–1.2)84 (22.0)1.1 (0.8–1.6)
value0.30.5
Time since HIV infection (years)
 <3.047 (16.6)1.044 (21.8)1.0
 3.0–5.923 (13.1)0.8 (0.5–1.2)34 (19.5)0.9 (0.6–1.3)
 ≥6.050 (20.0)1.2 (0.8–1.7)43 (27.9)1.3 (0.9–1.8)
value0.180.17
Lifetime HAART use
 No34 (14.0)1.046 (25.3)1.0
 Yes86 (18.4)1.3 (0.9–1.9)75 (21.6)0.9 (0.6–1.2)
value0.140.3
Lifetime protease inhibitor use
 No77 (22.7)1.068 (15.7)1.0
 Yes44 (23.0)1.0 (0.7–1.4)52 (18.8)1.2 (0.9–1.7)
value0.90.3
CD4 (cell/mm3)
 <35039 (15.1)1.050 (22.9)1.0
 ≥35080 (18.0)0.8 (0.6–1.2)69 (22.5)1.0 (0.7–1.4)
value0.30.9

HAART: highly active antiretroviral therapy; HCV: hepatitis C virus; HIV: human immunodeficiency virus; RR: risk ratio.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.